CONMED (CNMD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Voting matters and shareholder proposals
Seven directors nominated for election to the board, with a recommendation to vote for all nominees.
Advisory vote on executive compensation is recommended for approval.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026, is recommended.
Other business may be addressed as appropriate during the meeting or any adjournment.
Board of directors and corporate governance
Board election includes seven named nominees for directorship.
Executive compensation and say-on-pay
Advisory vote on named executive officer compensation is included as a key agenda item.
Partial view of Summaries dataset, powered by Quartr API
Latest events from CONMED
- 2025 guidance targets 4–6% revenue growth and $4.25–$4.40 adjusted EPS, with supply chain and currency headwinds.CNMD
Q4 20248 Jul 2026 - Q3 sales up 4.0%–4.3%, adjusted EPS up 16.7%, with CEO transition and hurricane impacts.CNMD
Q3 20248 Jul 2026 - Supply chain recovery, strong AirSeal performance, and margin growth drive a positive outlook.CNMD
2024 Wells Fargo Healthcare Conference8 Jul 2026 - Q2 sales and margins improved, but full-year guidance was reduced amid supply chain delays.CNMD
Q2 20248 Jul 2026 - All proposals, including Director elections and auditor ratification, were approved by majority vote.CNMD
AGM 202618 May 2026 - Net income and margins rose despite a 1.3% sales drop; organic growth outlook improved.CNMD
Q1 202630 Apr 2026 - 2026 guidance targets $1.345–$1.450B revenue and $4.25–$4.45 EPS, led by innovation and portfolio focus.CNMD
44th Annual J.P. Morgan Healthcare Conference16 Apr 2026 - Strong 2025 growth, board refreshment, and enhanced governance with key shareholder votes ahead.CNMD
Proxy filing7 Apr 2026 - 2025 sales and adjusted EPS rose, with 2026 guidance projecting further organic growth.CNMD
Q4 20253 Feb 2026